Topical Tranexamic Acid Reduces Blood Loss in Minimally Invasive Total Knee Arthroplasty Receiving Rivaroxaban

Table 3

Safety outcomes.

Event	Placebo (n = 30)	IV (n = 31)	Topical (n = 32)	p
Up to 3 months
Pulmonary embolism	0/30	0/31	0/31
Symptomatic deep-vein thrombosis	0/30	1/31	0/31
Return to OR because of wound complication (deep infection)	0/30 (0.0%)	0/31 (0.0%)	1/31 (3.1%)	1.000
Ecchymosis	7/30 (23.3%)	4/31 (12.9%)	4/31 (12.5%)	0.244
Hematoma	3/30 (10%)	6/31 (19.4%)	5/31 (15.6%)	0.308
Death	0/30 (0.0%)	0/31 (0.0%)	1/32 (3.1%)	1.000

patient in the topical group died of endemic Dengue fever after discharge from the hospital; : operating theater.